Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Bortezomib in Patients With Advanced or Metastatic Sarcoma

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	18 and over	NCI	MSKCC-01073 NCI-1757, NCT00027716, 1757

Trial Description

Purpose:

Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth.

Phase II trial to study the effectiveness of bortezomib in treating patients who have advanced or metastatic sarcoma.

Eligibility:

• At least 18 years old
• Measurable disease
• At least 4 weeks since biological therapy or radiation therapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive an infusion of bortezomib twice a week for 2 weeks. Treatment may be repeated every 3 weeks for as long as benefit is shown. Patients will be evaluated every 3 months for 1 year.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Memorial Sloan-Kettering Cancer Center

Robert Maki, MD, PhD, Protocol chair		Ph: 212-639-5720; 800-525-2225

Registry Information
Official Title		A Multi-Institutional, Open-Label, Two-Group, Phase II Study of PS-341 (LDP-341, NSC #681239) in Patients with Advanced or Metastatic Sarcoma
Trial Start Date		2001-10-02
Registered in ClinicalTrials.gov		NCT00027716
Date Submitted to PDQ		2001-10-12
Information Last Verified		2004-08-11
NCI Grant/Contract Number		N01-CM17105, P30-CA08748, U01-CA69913

Back to Top